Philip Tsai Buys 21,000 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai bought 21,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were acquired at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the purchase, the chief technology officer now directly owns 21,000 shares in the company, valued at approximately $198,030. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Immunome Price Performance

IMNM opened at $11.53 on Wednesday. The firm has a market capitalization of $719.70 million, a P/E ratio of -1.42 and a beta of 1.82. Immunome, Inc. has a one year low of $6.93 and a one year high of $30.96. The company has a fifty day moving average price of $12.49 and a 200-day moving average price of $13.55.

Hedge Funds Weigh In On Immunome

Institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in shares of Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after purchasing an additional 13,757 shares in the last quarter. Janus Henderson Group PLC grew its stake in Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after buying an additional 324,614 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Immunome by 113.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after buying an additional 1,194,451 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Immunome by 16.1% in the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock worth $49,847,000 after buying an additional 279,712 shares during the last quarter. Finally, Marshall Wace LLP raised its position in shares of Immunome by 228.5% during the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock valued at $20,731,000 after buying an additional 1,191,774 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Piper Sandler dropped their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Stephens began coverage on shares of Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome presently has an average rating of “Buy” and an average target price of $28.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.